Insider Buying: Medifast (NYSE:MED) Director Purchases 8,886 Shares of Stock

Medifast Inc (NYSE:MED – Get Free Report) Director Parsa Kiai bought 8,886 shares of Medifast stock in a transaction that occurred on Wednesday, November 18th. The stock was bought at an average price of $12.16 per share, for a total transaction of $108,053.76. Following the completion of the acquisition, the director directly owned 721,521 shares of the company’s stock, valued at $8,773,695.36. The trade was a 1.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Parsa Kiai also recently made the following trade(s):

  • On Thursday, November 19th, Parsa Kiai purchased 85,150 shares of Medifast stock. The shares were bought at an average price of $12.05 per share, with a total value of $1,026,057.50.
  • On Wednesday, November 4th, Parsa Kiai bought 661 shares of Medifast stock. The stock was purchased at an average cost of $13.03 per share, with a total value of $8,612.83.
  • On Wednesday, October 28th, Parsa Kiai bought 5,557 shares of Medifast stock. The stock was purchased at an average price of $12.24 per share, for a total transaction of $68,017.68.
  • On Wednesday, August 26th, Parsa Kiai acquired 43,150 shares of Medifast stock. The shares were bought at an average price of $12.26 per share, for a total transaction of $529,019.00.
  • On Monday, August 24th, Parsa Kiai bought 4,329 shares of Medifast stock. The stock was purchased at an average price of $12.00 per share, for a total transaction of $51,948.00.

Medifast Stock Down 1.9%

NYSE MED traded down $0.23 during trading on Friday, hitting $11.75. 107,868 shares of the stock traded hands, compared to its average volume of 200,250. The company has a market capitalization of $131.33 million, a P/E ratio of -3.18 and a beta of 0.65. The firm has a 50-day simple moving average of $12.15 and a 200-day simple moving average of $11.41. Medifast Inc has a 12-month low of $9.22 and a 12-month high of $13.63.

Medifast (NYSE:MED – Get Free Report) last issued its earnings results on Monday, October 26th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.16. Medifast had a negative net margin of 13.64% and a negative return on equity of 6.90%. The company had revenue of $72.05 million for the quarter, compared to analysts’ expectations of $71.30 million. As a group, research analysts predict that Medifast Inc will post -0.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on MED shares. Weiss Ratings cut shares of Medifast from a “sell (d)” rating to a “sell (d-)” rating in a research note on Wednesday, October 28th. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 11th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Medifast currently has a consensus rating of “Reduce” and an average price target of $12.00.

Check Out Our Latest Research Report on Medifast

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. American Century Companies Inc. increased its position in Medifast by 37.7% during the third quarter. American Century Companies Inc. now owns 439,221 shares of the specialty retailer’s stock worth $5,060,000 after buying an additional 120,310 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of Medifast in the third quarter valued at approximately $106,000. Ancora Advisors LLC grew its position in shares of Medifast by 411.5% during the third quarter. Ancora Advisors LLC now owns 36,110 shares of the specialty retailer’s stock worth $416,000 after acquiring an additional 29,050 shares during the last quarter. Marshall Wace LLP grew its position in shares of Medifast by 46.0% during the third quarter. Marshall Wace LLP now owns 352,704 shares of the specialty retailer’s stock worth $4,063,000 after acquiring an additional 111,055 shares during the last quarter. Finally, Commons Capital LLC increased its holdings in shares of Medifast by 23.0% in the 3rd quarter. Commons Capital LLC now owns 184,432 shares of the specialty retailer’s stock valued at $2,125,000 after acquiring an additional 34,516 shares during the period. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

(Get Free Report)

Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company’s approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company’s programs.

Featured Stories

Insider Buying and Selling by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.